B Cell Lymphoma
Article
Aggressive B-Cell Non-Hodgkin Lymphoma
News
Novartis CAR T-cell therapy adds a lymphoma indication
The new approval puts tisagenlecleucel head to head with Gilead’s axicabtagene ciloleucel.
News
FDA approves CAR T-cell therapy for lymphoma
The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah®) for its second indication. The chimeric antigen receptor (CAR)...
News
Background color a dermoscopic clue to cutaneous B-cell lymphoma
On dermoscopy, almost 80% of the lesions showed salmon- or yellow- to orange-colored background areas.
Conference Coverage
VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
News
Rituximab improves salvage in elderly B-cell lymphoma patients
Rituximab improved the 2-year survival rate from 20.7% to 46.8% for elderly patients with aggressive-B-cell lymphoma who relapsed after CHOP or R-...
News
Adding bortezomib to R-CHOP didn’t improve survival in diffuse large B-cell lymphoma
Could the phase-2 PYRAMID trial’s bortezomib dosing explain the lack of significant benefit?
Conference Coverage
Lupus and diffuse large B-cell lymphoma share genetic risk
Key clinical point: Two genetic risk variants for systemic lupus erythematosus also were clearly linked to risk of diffuse large B-cell lymphoma...
News
Routine imaging for diffuse large B-cell lymphoma offers no survival benefit
“An imaging-based follow-up strategy does not improve postremission [overall survival] for DLBCL,” wrote Dr. Tarec Christoffer El-Galaly, of...